Analysis
Thirty-five IPOs priced or scheduled to price in a single week -- per the Renaissance Capital pricing calendar -- 11 on Monday, 6 on Tuesday, 7 on Wednesday, 7 on Thursday and 4 more set for Friday -- is a pace that would have been unthinkable during the 2022-2024 IPO drought, when some full months saw fewer listings than this single week. Most of the volume is smaller offerings, SPACs and downsized deals rather than marquee names (Lyntris' downsized defense-sector debut this week is typical of the mix), but breadth matters here as much as any single headline: a market that can absorb 35 listings in a week, even mostly small ones, has real underwriting capacity and investor demand behind it.
That capacity is exactly what the marquee names still on deck -- Anthropic targeting a November pricing, Medline's expected $50 billion debut -- are counting on when they set final pricing terms in the months ahead. An IPO market that's been running hot for weeks gives underwriters a better read on real investor appetite and gives the big names a warmed-up book to price into, rather than testing a cold market single-handedly. The flip side is worth flagging too: this much volume pricing now means a wave of lockup expirations lands roughly six months out, which is a supply overhang worth watching for anyone holding positions into early 2027.